 |
|
Efficacy and Safety of Edifoligide
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: In the PREVENT (Project of Ex-vivo Vein Graft Engineering via Transfection) IV study, the PREVENT IV investigators1 found a high proportion of saphenous vein graft failure (VGF) (>25% of grafts) occurring within the first 12 to 18 months after coronary artery bypass graft (CABG) surgery, with more than 40% of the patients who underwent CABG surgery having at least 1 graft occluded within this period. Moreover, pretreatment of harvested saphenous veins with the E2F transcription factor decoy edifoligide with the aim of preventing neointimal hyperplasia and accelerated atherosclerosis did not reduce the failure rate of the venous conduits. The PREVENT IV investigators suggest that a substantial proportion of venous graft failures takes place early in the perioperative period as major adverse cardiac events occur soon after surgery, more frequently in association with graft failure, but they do not provide an explanation for this phenomenon.
Early occlusion of . . . [Full Text of this Article]
Alessandro Parolari, MD, PhD
aparolari@ccfm.it
Francesco Alamanni, MD;
Elena Tremoli, PhD;
Paolo Biglioli, MD
Centro Cardiologico Monzino IRCCS
Milan, Italy
RELATED ARTICLES
Efficacy and Safety of Edifoligide, an E2F Transcription Factor Decoy, for Prevention of Vein Graft Failure Following Coronary Artery Bypass Graft Surgery: PREVENT IV: A Randomized Controlled Trial
JAMA. ;294():2446-2454.
FULL TEXT
Efficacy and Safety of Edifoligide
and
JAMA. ;295():1513-1514.
FULL TEXT
Efficacy and Safety of Edifoligide
and
JAMA. ;295():1514-1514.
FULL TEXT
Efficacy and Safety of Edifoligide--Reply
, , , , , , and
JAMA. ;295():1514-1515.
FULL TEXT
|
